CD8A and neoplasm: In contrast, MTR-OralGem administration increased the frequencies of tumor-infiltrating CD3+CD4+ and CD3+CD8+ T cells compared to MTD-Gem-treated mice, and T effector cells reached levels similar to those of the control group (Figure 6A,B).